The Twisted Tale of Automated Pap Smear Screening
Executive Summary
After a long history of failures by companies developing new Pap smear testing technologies, a small group of companies seem close to commercializing systems that could transform cytology testin by automating at least a part of the procedure. But these companies have yet to prove to potential users that their instruments save money in the long term and greatly improve quality for a test that most lab users believe already has a relatively low error rate.
You may also be interested in...
VisionGate Inc.
In early 2001, after leaviing his post as executive chairman of TriPath Imaging, Alan Nelson founded VisionGate Inc., which is focused on developing a test for lung cancer screening. The technology he designed directly measures and quantifies structural changes in chromatin indicative of early-stage lung cancer, and uses proprietary optical microscopy that enables 3-D analysis. The result, he believes, is the first effective clinical screening test for this almost always fatal disease.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.